Clinical

Current Clinical Trials:

ASPIRE

Sponsor: United Therapeutics

Study Overview: A postmarketing observational study to assess respiratory tract adverse events in Pulmonary Arterial Hypertension (PAH) patients treated with Tyvaso® (Treprostinil) Inhalation Solution. Also, a comparison will be made to the type and incidence of events in patients receiving other FDA approved therapies for pulmonary arterial hypertension, as a control measure.

Target Population: Patients with pulmonary arterial hypertension being treated with Tyvaso or another FDA approved therapy

Study Status: Actively recruiting

Study Website Link: http://clinicaltrials.gov/ct2/show/NCT01266265

Principal Investigator: Bela Patel, MD

 

PAH QUERI EXT

Sponsor:  Actelion/Canadian Heart Research Center

Study Overview:  This research study is intended to follow subjects who have Pulmonary Arterial Hypertension (PAH) and require treatment. The goal of this study is to improve treatment guidelines and to better understand how doctors treating PAH use the recommended guidelines.

Target Population:  Patients with pulmonary arterial hypertension

Study Status:  Actively recruiting

Study Website: http://clinicaltrials.gov/ct2/show/NCT01389206

Principal Investigator:  Bela Patel, MD

 

FREEDOM EV

Sponsor:  United Therapeutics

Study Overview:  The purpose of this research study is to see how an investigational drug called UT-15C (treprostinil diethanolamine) works to treat PAH.  This study will look at the effect that UT-15C has on PAH symptoms and if the symptoms remain stable, improves, or worsens when added to your currently prescribed oral PAH therapy.  This will be compared to the effect that placebo has when added to your currently prescribed oral PAH therapy.  Patients who complete all required assessments will also be eligible to enter a long-term, open-label, extension study

Target Population:  Patients with pulmonary arterial hypertension

Study Status:  Actively recruiting

Study Website: http://clinicaltrials.gov/ct2/show/NCT01560624

Principal Investigator:  Bela Patel, MD

 

SYMPHONY

Sponsor:  Actelion

Study Overview:

The purpose of this clinical research study is:

1)      To evaluate a questionnaire called the PAH-SYMPACT to understand if it can measure quality of life in patients with pulmonary arterial hypertension;

2)      To find out more about the safety of the study drug, macitentan, for pulmonary arterial hypertension;

3)      To explore the effects of macitentan on PAH symptoms and their impact in patients with PAH.

Target Population:  Patients with pulmonary arterial hypertension

Study Status:  To begin recruitment soon

Study Website: http://clinicaltrials.gov/ct2/show/NCT01841762

Principal Investigator:  Bela Patel, MD

 

ART-123

Sponsor:  Asahi Kasei Pharma Corporation

Study Overview:

The purpose of this study is to see how well study drug ART-123 works at treating people with sepsis (a severe blood infection).  This study will also test the safety of ART-123 and look at the effect of ART-123.

Target Population:  Patients with severe sepsis

Study Status:  Actively recruiting

Study Website: http://clinicaltrials.gov/ct2/show/NCT01704001

Principal Investigator:  Bela Patel, MD

 

COOL-ARREST

Sponsor:  ZOLL Circulation, Inc

Study Overview:  This research study involves the investigational device called the IVTM System (which includes a cooling unit and a catheter) which cools a person’s body after cardiac arrest. Cooling a person’s body down (mild hypothermia) after cardiac arrest is believed to be beneficial to the brain and heart.  The purpose of the study is to see if the IVTM System can safely and effectively cool, maintain and rewarm the cardiac arrest subject.  Using this device in subjects is not new; subjects have been cooled, maintained and/or rewarmed using this system. This device has FDA approval for other uses.

Target Population:  Patients experiencing a cardiac arrest

Study Status:  Recruitment will begin soon

Study Website: http://clinicaltrials.gov/ct2/show/NCT01818388

Principal Investigator:  Pratik Doshi, MD

Stacy Burk, LVN
Research Coordinator II
P: 713-500-6851
F: 713-500-6829
E: Stacy.Burk@uth.tmc.edu